The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of bevacizumab on rate of oxaliplatin-induced thrombocytopenia and splenomegaly.
Kanwal Pratap Singh Raghav
No relevant relationships to disclose
Karime Kalil
No relevant relationships to disclose
Renata Ferrarotto
No relevant relationships to disclose
Binsah George
No relevant relationships to disclose
Cathy Eng
No relevant relationships to disclose
Chris R. Garrett
No relevant relationships to disclose
Evelyn Loyer
No relevant relationships to disclose
Paulo Hoff
No relevant relationships to disclose
Chusilp Charnsangavej
No relevant relationships to disclose
Scott Kopetz
No relevant relationships to disclose
Michael J. Overman
No relevant relationships to disclose